REMICADE® (infliximab) is a TNF inhibitor, a monoclonal antibody against tumor necrosis factor alpha (TNF-α), that is prescribed for the treatment of several autoimmune inflammatory diseases. REMICADE® is a prescription medication used to treat:
Can reduce signs and symptoms and induce and maintain remission in adult patients with moderately to severely active Crohn’s disease who haven’t responded well to other therapies
Can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steroids in adult patients with moderately to severely active ulcerative colitis who haven’t responded well to other therapies
Can reduce signs and symptoms, help stop further joint damage, and improve physical function in patients with moderately to severely active rheumatoid arthritis, in combination with methotrexate
Can reduce signs and symptoms of active arthritis, help stop further joint damage, and improve physical function in patients with psoriatic arthritis
Can reduce signs and symptoms in patients with active ankylosing spondylitis
Approved for the treatment of adult patients with chronic severe (extensive and/or disabling) plaque psoriasis under the care of a physician who will determine if REMICADE® is appropriate considering other available therapies
For more information, visit www.remicade.com.